Dapagliflozin in Chronic Kidney Disease: Insights from Network Pharmacology and Molecular Docking Simulation
Life · 11.03.2025 · 15 (3) · 437
DOI: 10.3390/life15030437 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life, online erschienen am 11.03.2025. Verfasst von Atthaphong Phongphithakchai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chronic kidney disease (CKD) involves inflammation, oxidative stress, and fibrosis, leading to renal dysfunction. Dapagliflozin, an SGLT2 inhibitor, shows renoprotective effects beyond glucose control, but its precise molecular mechanisms remain unclear. This study utilizes network pharmacology and molecular docking to elucidate its multi-target effects in CKD. Dapagliflozin’s SMILES structure was analyzed for ADMET properties. Potential targets were identified via SwissTargetPrediction, GeneCards, and SEA, and common CKD-related targets were determined. A protein–protein interaction (PPI) network was constructed, and key pathways were identified using GO and KEGG enrichment analyses. Molecular docking was conducted to validate dapagliflozin’s binding affinities with hub proteins. A total of 208 common targets were identified, including EGFR, GSK3β, and IL-6. GO and KEGG analyses highlighted key pathways, such as PI3K-Akt, MAPK, and AGE-RAGE, involved in inflammation, oxidative stress, and metabolic regulation. Molecular docking confirmed strong binding affinities with EGFR (−8.42 kcal/mol), GSK3β (−7.70 kcal/mol), and IL-6 (−6.83 kcal/mol). Dapagliflozin exhibits multi-target therapeutic potential in CKD by modulating inflammation, oxidative stress, and metabolic pathways. This integrative approach enhances the understanding of its mechanisms, supporting future experimental validation and clinical application in CKD management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nephrology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand.
- Department of Medical Technology, School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat 80160, Thailand.
- Research Excellence Center for Innovation and Health Products (RECIHP), Walailak University, Nakhon Si Thammarat 80160, Thailand.
- Endocrinology and Metabolism Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand.
- Division of Nephrology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
- Department of Biotechnology and Laboratory Science in Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
ORCID-Profile: Atthaphong Phongphithakchai, Thatsaphan Srithongkul, Jason C Huang, Moragot Chatatikun
Zitieren
APA
Phongphithakchai, A., Tedasen, A., Netphakdee, R., Leelawattana, R., Srithongkul, T., Raksasuk, S., Huang, J. C., & Chatatikun, M. (2025). Dapagliflozin in Chronic Kidney Disease: Insights from Network Pharmacology and Molecular Docking Simulation. Life, 15(3), 437. https://doi.org/10.3390/life15030437
Vancouver
Phongphithakchai A, Tedasen A, Netphakdee R, Leelawattana R, Srithongkul T, Raksasuk S, et al. Dapagliflozin in Chronic Kidney Disease: Insights from Network Pharmacology and Molecular Docking Simulation. Life. 2025;15(3):437. doi:10.3390/life15030437
BibTeX
@article{Phongphithakchai2025,
author = {Phongphithakchai, Atthaphong and Tedasen, Aman and Netphakdee, Ratana and Leelawattana, Rattana and Srithongkul, Thatsaphan and Raksasuk, Sukit and Huang, Jason C and Chatatikun, Moragot},
title = {Dapagliflozin in Chronic Kidney Disease: Insights from Network Pharmacology and Molecular Docking Simulation},
journal = {Life},
year = {2025},
volume = {15},
number = {3},
pages = {437},
doi = {10.3390/life15030437}
}
EUVIMED